Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 605 participants.

Also called NCT03551964

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 605 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03551964
  • EudraCT 2018-002161-19
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Czechia, France, Germany, Poland, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03551964. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-01 (actual); primary completion 2024-02-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Acronym
DAPT-SHOCK-AMI
Condition
Acute Myocardial Infarction
Condition
Cardiogenic Shock
Intervention (Drug)
Cangrelor
Intervention (Drug)
Ticagrelor
Lead sponsor
Faculty Hospital Kralovske Vinohrady (class: other government)
Collaborator
Charles University, Czech Republic (class: other)
Collaborator
Masaryk University (class: other)
Collaborator
Ministry of Health, Czech Republic (class: other government)
Collaborator
National Institute for Metabolic and Cardiovascular Disease Research (class: not stated)
Collaborator
Institute of Hematology and Blood Transfusion, Czech Republic (class: other)
Collaborator
BioVendor LM (class: not stated)

Record details

Record id
cardio:ct-nct03551964
Content hash
e78f1cdf803376486b04f22c565ed576c84902e0ffd6f2501717c6791a80fb84